The current wave of COVID-19 infections around the globe has resulted from a novel coronavirus employing its spike glycoprotein to bind with the protein binding sites of the host cells. These virus particles have the notorious tendency to proteolytically generate mutated biologically active fragments involved in signal transduction pathway resulting in the proliferation and transmission […]
Aptamers excel as binding reagents in ELISA replacement assays for antibiotics in complex media such as plasma, milk and others
18th May 2018.
Traditionally small molecules, such as antibiotics, have been difficult targets for ELISA development. Aptamer Group has selected aptamers that bind to small molecules, previously inaccessible to other binding technologies. Utilising our state-of-the-art automation and parallel processing techniques, we can select high affinity and highly specific aptamers against small molecule targets, in solution. These […]
Working at Aptamer Group:
The continued success of Aptamer Group means that the scientific team continues to grow. One member who joined us this summer is Katriona. Now she has had the chance to establish herself, we took the opportunity to catch up with her.
Hi Katriona, please tell us a little about yourself.
I am currently a […]
Message from the CEO
I am pleased to report that the trends mentioned in the last Newsletter continue to improve. We can now boast successful delivery of aptamers to a range of small and large molecule targets for customers in academia, biotech and big Pharma. We are also moving towards integration of aptamers into devices and […]
25th August, 2017
Starting with the end in mind
The use of aptamers in point of care diagnostic devices, for monitoring drug dose levels or for use as therapeutics, requires functionality across a wide variety of conditions.
Aptamer selection starts in conditions optimised to promote aptamer/target interaction to identify the best target-binders. Subsequently, by introducing different pressures, we […]
19th June 2017
Despite the current volatile environment for small businesses, Aptamer Group continues to grow and prosper. We are regularly delivering aptamers selected against small molecule and protein targets to our customers for a range of applications. The Aptamer Group is at an important stage of its evolution and in addition to collaborating with global […]